Xlife Sciences AG

curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine - Seite 2

For more information, please visit: www.xlifesciences.ch
 

About curasan AG
curasan develops, produces and markets biomaterials and medical devices for bone and tissue regeneration.
As a global technology leader in the future-oriented growth market of regenerative medicine, our company is specialized in biomimetic bone grafting materials mimicking biological structures for the use in orthopedics, traumatology, spine surgery and dental implantology.
Further information: https://www.curasan.de/en/company/about-us/

For media inquiries:
Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. [phone], [e-mail]

Andrea Weidner, Corporate Communications, curasan AG, Tel. [phone], [e-mail]

For scientific inquiries:
Dr. Frank Plöger, Chief Scientific Officer, Xlife Sciences AG, Tel. [phone],
[e-mail]

End of Media Release

---

Issuer: Xlife Sciences AG
Key word(s): Research/Technology

16.06.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Xlife Sciences AG
	Klausstrasse 19
	8008 Zürich
	Switzerland
Phone:	0041 44 385 84 60
E-mail:	[e-mail]
Internet:	www.xlifesciences.ch
ISIN:	CH0461929603
WKN:	A2PK6Z
Listed:	Regulated Unofficial Market in Frankfurt, Munich
EQS News ID:	1208372